Plan B could get conditional approval in May

04/29/2004 | Reuters

The CEO of Barr Pharmaceuticals said the FDA is likely to give conditional approval in May to switching the controversial morning-after contraceptive pill, called Plan B, from prescription to over-the-counter status. The FDA announced in February it would delay until May 21 its decision on the issue, and Barr CEO Bruce Downey said any further delay would only center on negotiations over label language.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX